Tentative FDA approval for Lamotrigine ANDA
FDA has granted approval to the Abbreviated New Drug Application (ANDA) filed by Taro Pharmaceutical Industries Ltd. for Lamotrigine Tablets. The product is used in the treatment of seizures and the tentative FDA approval means that the tablets meet the substantive requirements for approval, but can be marketed only after the final approval has been granted.
- FDA approves Cerebyx® generic version by Sun Pharma
- US Company Close to Gaining Approval for Scanning and Dye Procedure
- FDA Advisory Committee Recommends Approval Of Gilena
- Neuralstem receives FDA approval to test stem cell drug in humans
